started · updated
University of Lisbon researchers discover nanobodies that block Tau protein aggregation
Researchers at the University of Lisbon's Faculty of Sciences (FCUL) have discovered that nanobodies—small antibody fragments—can block various stages of Tau protein aggregation. This process is closely linked to the development of neurodegenerative conditions, including Alzheimer's disease.
The discovery occurred unexpectedly during research led by Professor Cláudio M. Gomes at the BioISI Institute. While the team was initially studying the S100B protein, which naturally helps protect the brain by controlling protein aggregation, they found that certain nanobodies developed for S100B could also directly recognize and interfere with Tau protein.
In cellular models, these nanobodies demonstrated varying levels of effectiveness, with one molecule successfully suppressing the aggregation and propagation of the protein. While this research does not represent a direct treatment for Alzheimer's, it provides new scientific tools for studying and potentially addressing neurodegenerative diseases.